You have free access to this content

Cancer

Cover image for Cancer

1 September 2009

Volume 115, Issue 17

Pages 3817–4041

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Commentary

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
      Developing quality indicators for cancer end-of-life care : Proceedings from a national symposium (pages 3820–3829)

      Hsien Seow, Claire F. Snyder, Lisa R. Shugarman, Richard A. Mularski, Jean S. Kutner, Karl A. Lorenz, Albert W. Wu and Sydney M. Dy

      Article first published online: 9 JUN 2009 | DOI: 10.1002/cncr.24439

      Quality indicators applicable to cancer have not been widely implemented. To advance this field, the authors worked with the Agency for Health Care Research and Quality and the National Cancer Institute to organize a national symposium to discuss key issues and future goals, based on a conceptual framework.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
      Chronic lymphocytic leukemia : Treatment options for patients with refractory disease (pages 3830–3841)

      Marina Motta, William G. Wierda and Alessandra Ferrajoli

      Article first published online: 17 JUN 2009 | DOI: 10.1002/cncr.24479

      Refractory chronic lymphocytic leukemia (CLL) has a poor prognosis. In the current study, the results obtained with chemotherapy, chemoimmunotherapy, and novel agents in patients with refractory CLL are reviewed and discussed.

    2. You have free access to this content
      The 2008 World Health Organization classification system for myeloproliferative neoplasms : Order out of chaos (pages 3842–3847)

      Ayalew Tefferi, Juergen Thiele and James W. Vardiman

      Article first published online: 26 MAY 2009 | DOI: 10.1002/cncr.24440

      The first formal classification of chronic myeloid neoplasms is credited to William Dameshek, who in 1951 described the concept of “myeloproliferative disorders (MPD)” by grouping together chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In 2001 and 2008, the World Health Organization introduced new classification systems for myeloproliferative neoplasms, taking a proactive role in translating emerging new science into clinical practice and building a consensus among pathologists, clinicians, and scientists.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Articles
    5. Original Articles
    6. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women (pages 3848–3857)

      Dawn L. Hershman, Donna Buono, Russell B. McBride, Wei Yann Tsai and Alfred I. Neugut

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24448

      The association between oncologist characteristics and the receipt of chemotherapy in elderly women with breast cancer was studied. Oncologists in a private practice were more likely to administer chemotherapy to their elderly patients with breast cancer than those employed in nonprivate setttings.

    2. Gastrointestinal Disease
      You have free access to this content
      Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer (pages 3858–3867)

      Heather Taffet Gold, Michael J. Hall, Victoria Blinder and Bruce R. Schackman

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24428

      The authors examined the cost effectiveness of using a pharmacogenetic test for uridine diphosphate glucuronosyltransferase 1A1*28 variant homozygosity before administering irinotecan to patients with metastatic colorectal cancer. Analyses indicated that such testing was slightly more cost effective than not testing, but only if an irinotecan dose reduction in homozygotes did not reduce efficacy, and that an investment of up to $22 million in a clinical study to evaluate reduced-dose efficacy in homozygotes should be considered.

    3. Genitourinary Disease
      You have free access to this content
      Anxiety and distress during active surveillance for early prostate cancer (pages 3868–3878)

      Roderick C. N. van den Bergh, Marie-Louise Essink-Bot, Monique J. Roobol, Tineke Wolters, Fritz H. Schröder, Chris H. Bangma and Ewout W. Steyerberg

      Article first published online: 27 JUL 2009 | DOI: 10.1002/cncr.24446

      Men with early prostate cancer in a protocol-based active surveillance program mainly reported favorable levels of anxiety and distress. Subgroups of men, especially those who had high neurotic personality scores, reported a higher burden of living with “untreated” cancer.

    4. You have free access to this content
      Rational approach to implementation of prostate cancer antigen 3 into clinical care (pages 3879–3886)

      Rou Wang, Arul M. Chinnaiyan, Rodney L. Dunn, Kirk J. Wojno and John T. Wei

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24447

      Prostate cancer antigen 3 (PCA3) may serve as a new target for prostate cancer detection, and adding urinary PCA3 testing to serum PSA had improved prostate cancer detection. PCA3 scores can help predict the risk of a positive biopsy, although larger scale validation studies are required.

    5. Gynecologic Oncology
      You have free access to this content
      Synergistic effect of rapamycin and cisplatin in endometrial cancer cells (pages 3887–3896)

      Victoria L. Bae-Jump, Chunxiao Zhou, John F. Boggess and Paola A. Gehrig

      Article first published online: 29 MAY 2009 | DOI: 10.1002/cncr.24431

      The authors provide evidence of a synergistic relation between rapamycin and cisplatin in both the inhibition of cell growth and induction of apoptosis. This suggests that rapamycin and cisplatin may be a rational combination of a targeted therapy for endometrial cancer.

    6. You have free access to this content
      MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinoma (pages 3897–3908)

      Ajoy K. Samanta, Helen J. Huang, Xiao-Feng Le, Weiqun Mao, Karen H. Lu, Robert C. Bast Jr and Warren S.-L. Liao

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24445

      MEKK3 is aberrantly expressed in ovarian cancers and may play an important role in tumors with constitutively activated nuclear factor κ B.

    7. Head and Neck Disease
      You have free access to this content
      Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx (pages 3909–3918)

      F. Christopher Holsinger, Heather Y. Lin, Vincent Bassot and Ollivier Laccourreye

      Article first published online: 23 JUN 2009 | DOI: 10.1002/cncr.24477

      For selected patients with squamous cell carcinoma of the larynx and pharynx who achieved a complete clinical response after platin-based induction chemotherapy, treatment exclusively with additional chemotherapy was feasible and produced excellent local control rates and comparable survival. The survival rates at 1-year and 5-years were 95.8% and 61.2%, respectively, and the final observed local control rate was 93%.

    8. Hematologic Malignancies
      You have free access to this content
      Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients : A retrospective, single-institution study (pages 3919–3923)

      John M. Granger and Dimitrios P. Kontoyiannis

      Article first published online: 23 JUN 2009 | DOI: 10.1002/cncr.24480

      A retrospective study of 758 solid tumor patients with extreme leukocytosis revealed that most (90%) had a secondary cause of their leukocytosis; infection was rare (15%). Approximately 10% of patients were diagnosed with a paraneoplastic leukemoid reaction, which was typically associated with advanced cancer and poor outcomes.

    9. You have free access to this content
      Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease : A Phase 2 Trial (pages 3924–3934)

      Nitin Jain, James M. Reuben, Hagop Kantarjian, Changping Li, Hui Gao, Bang-Ning Lee, Evan N. Cohen, Theresa Ebarb, David A. Scheinberg and Jorge Cortes

      Article first published online: 17 JUN 2009 | DOI: 10.1002/cncr.24468

      The use of heteroclitic peptides in chronic myelogenous leukemia may contribute to disruption in immune tolerance. In this study, 3 of 10 patients achieved a 1-log reduction in Bcr-Abl transcript levels.

    10. You have free access to this content
      Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure (pages 3935–3943)

      Alfonso Quintás-Cardama, Fabio Pires De Souza Santos, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Ahmed Awais, Gautam Borthakur and Jorge Cortes

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24432

      Characteristics of the cytopenias that occurred in patients with chronic myeloid leukemia in chronic phase who received dasatinib therapy after imatinib failure were investigated. Management of the cytopenias included transient dasatinib interruption in some patients and the addition of growth factors in some patients. Treatment interruption and/or dose reduction as well as growth factor support were effective strategies that were found to facilitate the continuous administration of dasatinib.

    11. Melanoma
      You have free access to this content
      Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma (pages 3944–3954)

      Jeffrey S. Weber, Hassan Zarour, Bruce Redman, Uwe Trefzer, Steven O'Day, Alfons J. M. van den Eertwegh, Ernest Marshall and Stefan Wagner

      Article first published online: 17 JUN 2009 | DOI: 10.1002/cncr.24473

      A phase 2 study was performed with CpG oligodeoxynucleotide PF-3512676 alone, together with dacarbazine (DTIC), and with DTIC alone to assess the objective responses to the regimens in unresectable melanoma. The objective response rates in the 3 PF-3512676 cohorts were not superior to DTIC alone and did not warrant continuation to the phase 3 portion of the study.

    12. Neuro-Oncology
      You have free access to this content
      Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis (pages 3955–3968)

      Thomas Palm, Dominique Figarella-Branger, Françoise Chapon, Catherine Lacroix, Françoise Gray, Francesco Scaravilli, David W. Ellison, Isabelle Salmon, Miikka Vikkula and Catherine Godfraind

      Article first published online: 17 JUN 2009 | DOI: 10.1002/cncr.24476

      By analyzing microarray-based expression profiles of a series of frozen ependymomas, the authors defined gene signatures specific to tumor localization and to World Health Organization grades. On the basis of these signatures, the authors related dysregulation of developmental—stem cell controlling—pathways to tumor localization, and the Wnt/β-catenin signaling pathway and several of its downstream or interacting pathways to anaplastic ependymomas.

    13. You have free access to this content
      Low-grade gliomas in older patients : Long-term follow-up from Mayo Clinic (pages 3969–3978)

      David A. Schomas, Nadia N. Laack and Paul D. Brown

      Article first published online: 17 JUN 2009 | DOI: 10.1002/cncr.24444

      This retrospective series of patients aged 55 years and older suggests that intracranial low-grade glioma behaves aggressively in this age group (median overall survival, 2.7 years). Aggressive management with maximally safe resection followed by adjuvant therapy should be strongly considered in this group.

    14. Discipline

      Disparities Research
      You have free access to this content
      Pancreatic resection : A key component to reducing racial disparities in pancreatic adenocarcinoma (pages 3979–3990)

      Melissa M. Murphy, Jessica P. Simons, Joshua S. Hill, Theodore P. McDade, Sing Chau Ng, Giles F. Whalen, Shimul A. Shah, Lynn H. Harrison Jr. and Jennifer F. Tseng

      Article first published online: 9 JUN 2009 | DOI: 10.1002/cncr.24433

      The authors used Surveillance, Epidemiology, and End Results Program data to identify patients with pancreatic adenocarcinoma and observed that black patients and white patients presented with similar disease stages and were recommended for pancreatectomy at similar rates, yet black patients underwent fewer resections. The results suggested that pancreatectomy may be underused for black patients and that maximizing resection rates for appropriate patients may be an important component in reducing outcome disparities among patients with pancreatic adenocarcinoma.

    15. You have free access to this content
      Racial and ethnic disparities in the incidence of invasive cervical cancer in Florida (pages 3991–4000)

      Nitin R. Patel, Dana E. Rollison, Jill Barnholtz-Sloan, Jill MacKinnon, Lee Green and Anna R. Giuliano

      Article first published online: 19 JUN 2009 | DOI: 10.1002/cncr.24427

      The authors investigated the increasing rate of invasive cervical cancer among African-American women aged >40 years in Florida that, coupled with diagnosis at a later stage of cancer, is of great concern. Most screening organizations recommend stopping screening at age 65 years. The observations from these analyses highlighted the need to focus prevention and screening efforts on African-American women living in Florida, and particularly women of postreproductive age.

    16. Outcomes Research
      You have free access to this content
      Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors (pages 4001–4009)

      Catherine E. Mosher, Richard Sloane, Miriam C. Morey, Denise Clutter Snyder, Harvey J. Cohen, Paige E. Miller and Wendy Demark-Wahnefried

      Article first published online: 27 JUL 2009 | DOI: 10.1002/cncr.24436

      Little is known regarding older cancer survivors' health behaviors and their associations with quality-of-life outcomes, especially during the long-term post-treatment period. The findings from this study suggested that many older long-term survivors of prostate, colorectal, and breast cancer practice suboptimal health habits and that improvements in diet, exercise, and body weight status may favorably influence physical quality-of-life outcomes.

    17. Pathology
      You have free access to this content
      Invasion characteristics of oral tongue cancer : Frequency of reporting and effect on survival in a population-based study (pages 4010–4020)

      Michael Goodman, Lihua Liu, Kevin Ward, Juanjuan Zhang, Lyn Almon, Gan Su, Lenard Berglund, Amy Chen, Uttam K. Sinha and John L. Young

      Article first published online: 23 JUN 2009 | DOI: 10.1002/cncr.24459

      Depth of invasion reporting increased from 13% during 1997 through 1999 to 23% during 2000 through 2004 after the College of American Pathologists issued its recommendations. Depth of tumor invasion of >3 mm and the presence of perineural invasion were found to be among the strongest predictors of survival in this population-based study.

    18. You have free access to this content
      Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups (pages 4021–4029)

      Inti Zlobec, Kristi Baker, Parham Minoo, Shinichi Hayashi, Luigi Terracciano and Alessandro Lugli

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24450

      A staging system based on primary tumor extent, lymph node status, and tumor border configuration was found to improve the prognostic classification of patients by 17.9% compared with TNM staging. In particular, stage II patients with an infiltrating border have poor clinical outcome and represent a subset of patients who could be considered for adjuvant treatment.

    19. Psychosocial Oncology
      You have free access to this content
      Prevalence and predictors of emotional and behavioural functioning of children where a parent has cancer : A multinational study (pages 4030–4039)

      Mikael Thastum, Maggie Watson, Christian Kienbacher, Jorma Piha, Barbara Steck, Robert Zachariae, Christiane Baldus and Georg Romer

      Article first published online: 10 JUN 2009 | DOI: 10.1002/cncr.24449

      Children and adolescents of a parent with cancer were of higher risk of psychosocial problems than norms. The best predictor of internalizing problems in children and adolescents was parental depression, and the best predictor of externalizing problems in children and adolescents was family dysfunction.

  5. Errata

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Articles
    5. Original Articles
    6. Errata
    1. You have free access to this content
      Erratum (page 4040)

      Article first published online: 22 JUL 2009 | DOI: 10.1002/cncr.24639

    2. You have free access to this content
      Erratum (page 4041)

      Article first published online: 10 JUL 2009 | DOI: 10.1002/cncr.24640

      This article corrects:

      Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas1

      Vol. 115, Issue 16, 3774–3781, Article first published online: 9 JUN 2009

SEARCH

SEARCH BY CITATION